pTVG-HP with rhGM-CSF

BIOLOGICAL2 trials

Sponsors

University of Wisconsin, Madison

Conditions

Prostate Cancer

Phase 1

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

CompletedNCT00582140

University of Wisconsin, MadisonProstate Cancer

Start: 2005-03-31End: 2008-08-31Updated: 2019-11-19

Phase 2

Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT00849121

University of Wisconsin, MadisonProstate Cancer

Start: 2009-03-16End: 2014-02-17Updated: 2019-11-21

Related Papers

Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer

Human Vaccines & Immunotherapeutics2024-08-295 citations

Abstract B147: Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with recurrent prostate cancer (NCT01341652)

Cancer Immunology Research2016-01-012 citations